Castle Biosciences (CSTL) Operating Expenses (2018 - 2026)

Castle Biosciences has disclosed Operating Expenses across 9 years of filings, most recently posting $102.1 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $102.1 million, down 11.93% year-over-year; the trailing twelve-month figure through Mar 2026 was $373.2 million (up 3.42% YoY), and the FY2025 annual result was $387.0 million, up 19.68% from the prior year.
• Operating Expenses came in at $102.1 million for Q1 2026 at Castle Biosciences, up from $90.8 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $115.9 million in Q1 2025 to a low of $38.8 million in Q2 2022.
• The 5-year median for Operating Expenses is $78.4 million (2024), against an average of $77.1 million.
• Across the five-year window, Operating Expenses jumped 113.42% in 2022 and decreased 11.93% in 2026, its largest moves.
• Castle Biosciences' Operating Expenses stood at $61.2 million in 2022, then advanced by 17.34% to $71.8 million in 2023, then climbed by 14.6% to $82.3 million in 2024, then advanced by 10.43% to $90.8 million in 2025, then increased by 12.38% to $102.1 million in 2026.
• The last three Operating Expenses figures came in at $102.1 million (Q1 2026), $90.8 million (Q4 2025), and $89.8 million (Q3 2025), per Business Quant data.